Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

November 27, 2020

EMA validates application for Tepotinib for treatment of advanced NSCLC with METex14 skipping alterations

Merck announced that the European Medicines Agency (EMA) has validated for review, the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.

EMA validates application for Tepotinib for treatment of advanced NSCLC with METex14 skipping alterations